Treatment Refractory MAC Lung Disease clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
open to eligible people ages 18-85
This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)
at UC Davis UCSF
Our lead scientists for Treatment Refractory MAC Lung Disease research studies include Scott Crabtree, MD Catherine Devoe, MD Mohamed Fayed, MD, FCCP.
Last updated: